Bausch Health Companies (BHC) EBITDA (2009 - 2026)

Bausch Health Companies has disclosed EBITDA across 18 years of filings, most recently posting $740.0 million for Q2 2026.

• In Q2 2026, EBITDA rose 66.67% year-over-year to $740.0 million; the TTM figure through Jun 2026 stood at $883.0 million (down 44.67% YoY), while the FY2025 annual figure was $1.8 billion, up 17.27% from the prior year.
• EBITDA came in at $740.0 million for Q2 2026 at Bausch Health Companies, up from -$950.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $740.0 million in Q2 2026 to a low of -$950.0 million in Q1 2026.
• Average EBITDA over 5 years is $253.7 million, with a median of $301.5 million recorded in 2022.
• Year-over-year, EBITDA soared 2171.43% in 2024 and tumbled 444.2% in 2026.
• Over 5 years, EBITDA stood at -$236.0 million in 2022, then surged by 253.39% to $362.0 million in 2023, then surged by 54.14% to $558.0 million in 2024, then retreated by 15.05% to $474.0 million in 2025, then soared by 56.12% to $740.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $740.0 million in Q2 2026, -$950.0 million in Q1 2026, and $474.0 million in Q4 2025.